Drugs / Rituximab Biosimilar
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT06890884 Background | Apr 2025 → Dec 2027 expected | diffuse large B-cell lymphoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 2 | NCT05406401 Background | Jul 2022 → Apr 2029 expected | diffuse large B-cell lymphoma | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06717347 Background | Jan 2025 → Jul 2029 expected | diffuse large B-cell lymphoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rituximab Biosimilar | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06717347 ↗ |
| Route | Intravenous | “IV infusion” NCT05406401 ↗ |